Objective To develop and assess the feasibility of a simplified Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score for quantifying disease activity changes in patients with axial spondyloarthritis (axSpA) undergoing biological therapy, and compare its performance with the original SPARCC score. Materials and methods This prospective feasibility study included 60 axSpA patients receiving biological therapy. MRI examinations of the sacroiliac joints and spine were performed at baseline and six months after the initiation of biological therapy. The simplified SPARCC score, focusing on the three most affected slices/vertebrae instead of six, was developed and compared with the original SPARCC score. Both scores were correlated with clinical indices and inflammatory markers. Inter-reader agreement and sensitivity to inflammatory changes were evaluated to assess reliability and research utility. Results Both scores showed significant improvement after six months of initiating biological therapy (p < 0.001). The simplified SPARCC scores correlated strongly with disease activity markers, comparable to or stronger than the original scores, with median score reductions of 71.4–79.1%. Inter-reader agreement was substantial to almost perfect for all scores, with simplified SPARCC spine score exhibiting the highest agreement (κ = 0.817 at baseline and 0.784 at follow-up). The simplified score significantly reduced assessment time compared with the original score (11 vs 37 min, p < 0.001). Conclusion The simplified SPARCC MRI score is a promising research tool for assessing disease activity in axSpA patients, with the advantages of improved inter-reader reliability and significantly reduced assessment time. Further validation is required to confirm its broader clinical applicability. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> Can a simplified SPARCC MRI score reduce assessment time while reliably tracking disease activity changes? <Emphasis Type="BoldItalic">Findings</Emphasis> The simplified SPARCC MRI score showed comparable sensitivity to change and reliability vs the original score, reducing mean assessment time from 37 min to 11 min. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> The simplified SPARCC MRI score provides a faster, reliable research method for tracking axSpA activity changes, potentially improving clinical trial efficiency. Further validation is needed to confirm routine clinical utility. Graphical Abstract

Time-efficient MRI scoring system for axial spondyloarthritis: a feasibility study

期刊论文
发表日期：

2025年7月30日

查看全文

Fatma I. Abdelrahman,
Mohammad Abd Alkhalik Basha,
El-sayed A.H.F. El-sayad,
Heba Abdelwahab Seliem,
Mohamed Hesham Saleh Saleh Radwan,
Rania Mostafa A. Hassan,
Hamada M. Khater,
Ahmed M. Abdelkhalik Basha,
Mohamed Atia Mortada

摘要

Objective

To develop and assess the feasibility of a simplified Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score for quantifying disease activity changes in patients with axial spondyloarthritis (axSpA) undergoing biological therapy, and compare its performance with the original SPARCC score.

Materials and methods

This prospective feasibility study included 60 axSpA patients receiving biological therapy. MRI examinations of the sacroiliac joints and spine were performed at baseline and six months after the initiation of biological therapy. The simplified SPARCC score, focusing on the three most affected slices/vertebrae instead of six, was developed and compared with the original SPARCC score. Both scores were correlated with clinical indices and inflammatory markers. Inter-reader agreement and sensitivity to inflammatory changes were evaluated to assess reliability and research utility.

Results

Both scores showed significant improvement after six months of initiating biological therapy (p < 0.001). The simplified SPARCC scores correlated strongly with disease activity markers, comparable to or stronger than the original scores, with median score reductions of 71.4–79.1%. Inter-reader agreement was substantial to almost perfect for all scores, with simplified SPARCC spine score exhibiting the highest agreement (κ = 0.817 at baseline and 0.784 at follow-up). The simplified score significantly reduced assessment time compared with the original score (11 vs 37 min, p < 0.001).

Conclusion

The simplified SPARCC MRI score is a promising research tool for assessing disease activity in axSpA patients, with the advantages of improved inter-reader reliability and significantly reduced assessment time. Further validation is required to confirm its broader clinical applicability.

Key Points

Question Can a simplified SPARCC MRI score reduce assessment time while reliably tracking disease activity changes?

Findings The simplified SPARCC MRI score showed comparable sensitivity to change and reliability vs the original score, reducing mean assessment time from 37 min to 11 min.

Clinical relevance The simplified SPARCC MRI score provides a faster, reliable research method for tracking axSpA activity changes, potentially improving clinical trial efficiency. Further validation is needed to confirm routine clinical utility.

Graphical Abstract